News
EQS-News: Abivax publishes financial reports with the French and U.S. securities regulatory agencies
GenSight Biologics Reports Cash Position as of March 31, 2024, and Provides Business Update
Regulatory News:
GenSight Biologics ("GenSight Biologics" or the "Company") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing
GenSight Biologics Announces its 2024 Financial Calendar
Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
EQS-News: Abivax reports 2023 financial results and operational update
Poxel to Report Its 2023 Annual Results by the End of April 2024
Regulatory News:
POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic
Resolutions of the Annual Shareholders’ Meeting of Sartorius Stedim Biotech S.A.
GenSight Biologics Reports Full Year 2023 Consolidated Financial Results
Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal
Sensorion Announces the Availability of Its Letter to Shareholders
Regulatory News:
Sensorion (FR0012596468 – ALSEN) (Paris:ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and
Sensorion Announces its Participation in the Annual Bioprocessing Summit Europe
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within
Sensorion Reports Full-Year 2023 Financial Results and Business Update
Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and
Sensorion Announces the Availability of its Financial Report for 2023
Regulatory News:
Sensorion (FR0012596468 – ALSEN) (Paris:ALSEN), a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat, and
Sensorion Announces it Has Met Primary Endpoint for SENS-401 Phase 2a Clinical Study for Residual Hearing Preservation
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent hearing
Guerbet strengthens its Executive Committee with two new appointments to consolidate its medium and long-term ambitions.
Sensorion Will Host a Webcast on March 14, 2024, to Announce its 2023 Annual Financial Results
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within
GenSight Biologics Announces LUMEVOQ® Scientific Updates at NANOS 2024
Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for retinal
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sensorion Announces its Participation in the Leerink Partners Global Biopharma Conference
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within
Sartorius Stedim Biotech SA: Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
Sartorius Stedim Biotech releases Universal Registration Document 2023
Sartorius Stedim Biotech: Information on Document Availability
ABIONYX Pharma Acknowledges the Clinical Results of the Phase 3 AEGIS-II Study Evaluating the Efficacy and Safety of CSL Behring’s Human-plasma-derived apoA-I, CSL112
Access here the full press release
ABIONYX Pharma, (FR0012616852 – ABNX – PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies
Poxel Reports Cash and Revenue for the Full Year 2023 and Provides Corporate Update
Regulatory News:
POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic